Production (Stage)
Kezar Life Sciences, Inc.
KZR
$4.40
$0.020.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | 16.03M | 16.24M | 16.30M | -- |
| Gross Profit | -- | -16.03M | -16.24M | -16.30M | -- |
| SG&A Expenses | 5.45M | 5.55M | 5.71M | 5.60M | 6.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.63M | 21.58M | 21.95M | 21.90M | 23.71M |
| Operating Income | -17.63M | -21.58M | -21.95M | -21.90M | -23.71M |
| Income Before Tax | -16.56M | -20.22M | -20.31M | -21.55M | -21.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.56M | -20.22M | -20.31M | -21.55M | -21.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.56M | -20.22M | -20.31M | -21.55M | -21.66M |
| EBIT | -17.63M | -21.58M | -21.95M | -21.90M | -23.71M |
| EBITDA | -17.38M | -21.32M | -21.69M | -21.64M | -23.45M |
| EPS Basic | -2.27 | -5.54 | -2.78 | -2.96 | -2.98 |
| Normalized Basic EPS | -1.42 | -3.46 | -1.74 | -1.72 | -1.86 |
| EPS Diluted | -2.27 | -5.54 | -2.78 | -2.96 | -2.98 |
| Normalized Diluted EPS | -1.42 | -3.46 | -1.74 | -1.72 | -1.86 |
| Average Basic Shares Outstanding | 7.31M | 7.30M | 7.30M | 7.28M | 7.28M |
| Average Diluted Shares Outstanding | 7.31M | 7.30M | 7.30M | 7.28M | 7.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |